Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Amcenestrant
Drug: Everolimus
Drug: Palbociclib
Drug: Alpelisib
Drug: Abemaciclib

First Posted Date: 2017-09-15

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 136

Registration Number: NCT03284957

Locations: 🇨🇦
Investigational Site Number : 1240003, Vancouver, British Columbia, Canada
🇨🇦
Investigational Site Number : 1240002, Toronto, Ontario, Canada
🇨🇿
Investigational Site Number : 2030002, Brno, Czechia

and more 22 locations

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1

Completed

Conditions: Recurrent and Refractory Solid Tumors

Interventions: Drug: Lenvatinib
Drug: Everolimus

First Posted Date: 2017-08-10

Last Posted Date: 2023-08-30

Lead Sponsor: Eisai Inc.

Target Recruit Count: 64

Registration Number: NCT03245151

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Southern California Permanente Medical Group, Los Angeles, California, United States

and more 47 locations

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2

Conditions: Rare Tumor
Refractory Tumor

Interventions: Drug: Gefitinib
Drug: Erlotinib
Drug: Afatinib
Drug: Trastuzumab
Drug: Oxazolidine
Drug: Olaparib
Drug: Everolimus
Drug: Cabozantinib
Drug: Vemurafenib
Drug: Dabrafenib
Drug: Palbociclib
Drug: PD-1/L1 inhibitor plus anti-angiogenic agent

First Posted Date: 2017-08-03

Last Posted Date: 2022-03-04

Lead Sponsor: Baodong Qin

Target Recruit Count: 300

Registration Number: NCT03239015

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

Phase 4

Completed

Conditions: BK Virus Nephropathy After Kidney Transplantation

Interventions: Drug: everolimus

First Posted Date: 2017-07-13

Last Posted Date: 2024-08-19

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 130

Registration Number: NCT03216967

Locations: 🇫🇷
CHU - Hôpital Dupuytren, Limoges, France
🇫🇷
CHRU d'Angers, Angers, France
🇫🇷
CHU - Hôpital Sud, Amiens, France

and more 11 locations

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Phase 3

Completed

Conditions: Post Menopausal Breast Cancer

Interventions: Drug: everolimus
Drug: exemestane

First Posted Date: 2017-06-05

Last Posted Date: 2020-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 235

Registration Number: NCT03176238

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: lenvatinib
Drug: everolimus

First Posted Date: 2017-06-02

Last Posted Date: 2024-02-01

Lead Sponsor: Eisai Inc.

Target Recruit Count: 343

Registration Number: NCT03173560

Locations: 🇦🇺
Northern Cancer Institute, Saint Leonards, Saint Leonards, New South Wales, Australia
🇨🇿
Nemocnice Na Bulovce, Prague, Czechia
🇺🇸
Optimal Research, Honolulu, Hawaii, United States

and more 90 locations

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: CB-839
Drug: Placebo
Drug: everolimus

First Posted Date: 2017-05-23

Last Posted Date: 2022-09-15

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 69

Registration Number: NCT03163667

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
University Cancer & Blood Center, LLC, Athens, Georgia, United States
🇺🇸
Florida Cancer Specialists- North, Saint Petersburg, Florida, United States

and more 35 locations

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1

Completed

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: niraparib
Drug: everolimus

First Posted Date: 2017-05-16

Last Posted Date: 2024-08-01

Lead Sponsor: Avera McKennan Hospital & University Health Center

Target Recruit Count: 14

Registration Number: NCT03154281

Locations: 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Phase 2

Suspended

Conditions: Thyroid Cancer

Interventions: Drug: Lenvatinib
Drug: Everolimus

First Posted Date: 2017-05-04

Last Posted Date: 2021-10-15

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 5

Registration Number: NCT03139747

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2

Active, not recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ribociclib
Drug: Everolimus

First Posted Date: 2017-04-14

Last Posted Date: 2024-07-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 48

Registration Number: NCT03114527

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy